Leyre Oteiza Zubiri, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 21 | 2024 | 22131 | 0.630 |
Why?
|
Myocarditis | 6 | 2024 | 788 | 0.600 |
Why?
|
Melanoma | 10 | 2023 | 5697 | 0.460 |
Why?
|
Immunotherapy | 4 | 2021 | 4642 | 0.430 |
Why?
|
Cross Infection | 1 | 2021 | 1422 | 0.390 |
Why?
|
Exanthema | 2 | 2024 | 503 | 0.310 |
Why?
|
Colitis | 3 | 2024 | 1234 | 0.310 |
Why?
|
Blood | 1 | 2024 | 596 | 0.200 |
Why?
|
Thyroiditis | 1 | 2021 | 86 | 0.190 |
Why?
|
Hypokalemia | 1 | 2021 | 153 | 0.180 |
Why?
|
Drug Eruptions | 2 | 2024 | 335 | 0.180 |
Why?
|
Extracellular Matrix Proteins | 2 | 2015 | 829 | 0.180 |
Why?
|
Lung Neoplasms | 5 | 2024 | 13382 | 0.180 |
Why?
|
Lymphatic Diseases | 1 | 2022 | 320 | 0.180 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.170 |
Why?
|
Retrospective Studies | 26 | 2024 | 80566 | 0.170 |
Why?
|
Enterocolitis | 1 | 2020 | 106 | 0.160 |
Why?
|
Pericardial Effusion | 1 | 2021 | 247 | 0.160 |
Why?
|
Hyponatremia | 1 | 2021 | 279 | 0.160 |
Why?
|
International Classification of Diseases | 1 | 2024 | 909 | 0.160 |
Why?
|
Lymphocyte Count | 1 | 2020 | 778 | 0.150 |
Why?
|
Ablation Techniques | 1 | 2021 | 246 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5319 | 0.150 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 147 | 0.140 |
Why?
|
Budgets | 1 | 2019 | 230 | 0.140 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 737 | 0.140 |
Why?
|
Middle Aged | 29 | 2024 | 220584 | 0.140 |
Why?
|
Aged | 27 | 2024 | 169042 | 0.130 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 2447 | 0.130 |
Why?
|
Humans | 52 | 2024 | 760617 | 0.130 |
Why?
|
Skin Neoplasms | 4 | 2024 | 5812 | 0.130 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2015 | 105 | 0.130 |
Why?
|
Heart Conduction System | 1 | 2021 | 992 | 0.130 |
Why?
|
Inpatients | 3 | 2021 | 2544 | 0.120 |
Why?
|
Male | 34 | 2024 | 360358 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1051 | 0.120 |
Why?
|
Chemistry, Clinical | 1 | 2015 | 64 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1879 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2014 | 2057 | 0.120 |
Why?
|
Combined Modality Therapy | 3 | 2022 | 8516 | 0.110 |
Why?
|
Celiac Disease | 1 | 2022 | 819 | 0.110 |
Why?
|
Patient Admission | 1 | 2021 | 1365 | 0.110 |
Why?
|
Action Potentials | 1 | 2021 | 1825 | 0.110 |
Why?
|
Brachytherapy | 1 | 2021 | 1223 | 0.110 |
Why?
|
S100 Proteins | 1 | 2013 | 217 | 0.110 |
Why?
|
Intestinal Mucosa | 1 | 2024 | 3031 | 0.110 |
Why?
|
Hemoglobins | 1 | 2019 | 1524 | 0.100 |
Why?
|
Neoplasm Proteins | 2 | 2015 | 3607 | 0.100 |
Why?
|
Female | 29 | 2024 | 392148 | 0.100 |
Why?
|
Myocardium | 1 | 2024 | 4724 | 0.100 |
Why?
|
Hospitalization | 4 | 2024 | 10704 | 0.090 |
Why?
|
Exosomes | 1 | 2015 | 424 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2021 | 1418 | 0.090 |
Why?
|
Drug Costs | 1 | 2019 | 1183 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1662 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2143 | 0.090 |
Why?
|
Incidence | 6 | 2024 | 21337 | 0.080 |
Why?
|
Heart Rate | 1 | 2021 | 4180 | 0.080 |
Why?
|
Cohort Studies | 8 | 2024 | 41457 | 0.080 |
Why?
|
Plaque, Atherosclerotic | 1 | 2020 | 1532 | 0.080 |
Why?
|
Troponin T | 2 | 2024 | 780 | 0.080 |
Why?
|
Aged, 80 and over | 9 | 2024 | 58894 | 0.080 |
Why?
|
Neutrophils | 1 | 2020 | 3763 | 0.070 |
Why?
|
Electrocardiography | 1 | 2021 | 6346 | 0.070 |
Why?
|
Risk Factors | 10 | 2024 | 74115 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1924 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 2249 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4110 | 0.070 |
Why?
|
Polymerase Chain Reaction | 1 | 2014 | 6074 | 0.060 |
Why?
|
Ventricular Myosins | 1 | 2024 | 65 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7512 | 0.060 |
Why?
|
Atherosclerosis | 1 | 2020 | 3400 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8645 | 0.060 |
Why?
|
DNA | 2 | 2015 | 7196 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 91 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7389 | 0.060 |
Why?
|
Neoplasm Staging | 4 | 2019 | 11116 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12661 | 0.050 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2015 | 411 | 0.050 |
Why?
|
Consensus | 2 | 2024 | 3117 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2021 | 64568 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 143 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2019 | 9172 | 0.050 |
Why?
|
Time Factors | 5 | 2021 | 39913 | 0.050 |
Why?
|
Glomerular Filtration Rate | 2 | 2021 | 2178 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8529 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4845 | 0.050 |
Why?
|
Electrolytes | 1 | 2021 | 274 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2022 | 15251 | 0.050 |
Why?
|
Autoantigens | 1 | 2024 | 888 | 0.040 |
Why?
|
Troponin I | 1 | 2024 | 650 | 0.040 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13635 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2020 | 11459 | 0.040 |
Why?
|
Microscopy | 1 | 2024 | 905 | 0.040 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2021 | 123 | 0.040 |
Why?
|
Risk Assessment | 4 | 2021 | 23972 | 0.040 |
Why?
|
Biopsy | 2 | 2021 | 6762 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 199 | 0.040 |
Why?
|
Adult | 9 | 2024 | 220969 | 0.040 |
Why?
|
Cardiac Imaging Techniques | 1 | 2021 | 266 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 634 | 0.040 |
Why?
|
Massachusetts | 2 | 2021 | 8833 | 0.040 |
Why?
|
Prognosis | 4 | 2020 | 29600 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1779 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6807 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20556 | 0.040 |
Why?
|
Proteomics | 2 | 2024 | 3836 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2020 | 790 | 0.030 |
Why?
|
Sodium | 1 | 2021 | 1588 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4910 | 0.030 |
Why?
|
Colon | 1 | 2024 | 1791 | 0.030 |
Why?
|
Cell Lineage | 1 | 2024 | 2554 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2024 | 1163 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2546 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 965 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 1040 | 0.030 |
Why?
|
Databases, Factual | 2 | 2021 | 7960 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1517 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2024 | 22148 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3268 | 0.030 |
Why?
|
Models, Economic | 1 | 2019 | 714 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 530 | 0.030 |
Why?
|
Registries | 2 | 2021 | 8207 | 0.030 |
Why?
|
Fibroblasts | 1 | 2024 | 4137 | 0.030 |
Why?
|
Creatinine | 1 | 2019 | 1896 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2024 | 2722 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 303 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3575 | 0.030 |
Why?
|
Disease Progression | 2 | 2020 | 13495 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1722 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2016 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2024 | 3672 | 0.020 |
Why?
|
Heart | 1 | 2024 | 4403 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1467 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2024 | 4745 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2024 | 3077 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4571 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2756 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 30016 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2515 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2024 | 3415 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3873 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3683 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2160 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1998 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1175 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5486 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9417 | 0.020 |
Why?
|
Skin | 1 | 2022 | 4473 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2015 | 943 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10754 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4174 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2015 | 1483 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2812 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3039 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3742 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54360 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2024 | 4803 | 0.020 |
Why?
|
Indoles | 1 | 2014 | 1830 | 0.020 |
Why?
|
Kidney | 1 | 2021 | 7045 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5835 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 5491 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3244 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10505 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6987 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12719 | 0.020 |
Why?
|
Sulfonamides | 1 | 2014 | 1977 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6474 | 0.010 |
Why?
|
United States | 2 | 2021 | 72272 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15828 | 0.010 |
Why?
|
Cytokines | 1 | 2015 | 7373 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16967 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2013 | 5672 | 0.010 |
Why?
|
Quality of Life | 1 | 2019 | 13347 | 0.010 |
Why?
|
Young Adult | 1 | 2022 | 59179 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15498 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39063 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 88234 | 0.010 |
Why?
|